Jessee M. Jaynes - 08 May 2025 Form 4 Insider Report for Genvor Inc

Reporting relationship: Chief Research Officer, Director
Issuer ticker: GNVR on OTC
Reported as of: 08 May 2025
Net transaction value: +$286,000
SEC form: 4
Accepted by SEC: 05 Dec 2025, 16:06:25 UTC
Prior SEC filing: 05 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Dr. Jesse Jaynes

Key filing fact

Jessee M. Jaynes filed Form 4 for Genvor Inc on 05 Dec 2025.

Key facts

This page summarizes Jessee M. Jaynes's Form 4 filing for Genvor Inc.
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 05 Dec 2025, 16:06.

Change

Previous filing in this sequence was filed on 05 Dec 2025.
Current net transaction value: +$286,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002075345 Primary reporting owner

Jaynes Jessee M

Relationship: Chief Research Officer, Director
Address: 1550 W HORIZON RIDGE PKWY, STE R #3040, HENDERSON
Signature: /s/ Dr. Jesse Jaynes
Signature date: 05 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GNVR transaction

Common Stock

Award

Transaction value: $100,000
Shares: +400,000
Change %
Price: $0.2500
Shares after: 400,000
Date: 08 May 2025
Ownership: Direct
Footnotes: F1

GNVR transaction

Common Stock

Award

Transaction value: $186,000
Shares: +124,000
Change %: +31%
Price: $1.50
Shares after: 524,000
Date: 02 Dec 2025
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Conversion of $100,000 in accrued payables due to Dr. Jaynes at $0.25/share.

Footnote F2

Conversion of $186,000 in accrued payables due to Dr. Jaynes at $1.50/share.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .